Physician

Nishanth Sukumaran, MD

According to 2025 Medicare claims, Nishanth Sukumaran, MD (NPI: 1538328844) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Hopewell City, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23805-0002.

Sukumaran's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 615 traditional Medicare patients, billed 72,294 HCPCS/CPT codes, and received $1,828,924 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,300 prescription claims across 234 beneficiaries totaling $2,600,930 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 11 claims. Open Payments data shows 89 records totaling $1,997. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,160,301 to $1,828,924. Similarly, Part D prescription costs have risen steadily, from $1,411,339 to $2,600,930. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.2M$2.4M2015 Medicare payment: $1,160,301 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $1,180,474 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,334,914 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $2,074,470 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $1,483,085 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $1,828,250 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $1,743,347 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $2,036,102 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $2,391,193 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $1,828,924 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
201553599,099$1,160,301
201661284,713$1,180,474
201779390,908$1,334,914
2018756162,907$2,074,470
2019732126,149$1,483,085
2020722114,787$1,828,250
2021693111,805$1,743,347
2022640103,533$2,036,102
2023633108,008$2,391,193
202461572,294$1,828,924

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$1.3M$2.6M2015 Drug cost: $1,411,339 (USD; Tot_Drug_Cst)2016 Drug cost: $947,728 (USD; Tot_Drug_Cst)2017 Drug cost: $1,455,239 (USD; Tot_Drug_Cst)2018 Drug cost: $2,053,950 (USD; Tot_Drug_Cst)2019 Drug cost: $2,140,815 (USD; Tot_Drug_Cst)2020 Drug cost: $1,908,264 (USD; Tot_Drug_Cst)2021 Drug cost: $1,522,759 (USD; Tot_Drug_Cst)2022 Drug cost: $1,704,819 (USD; Tot_Drug_Cst)2023 Drug cost: $1,809,225 (USD; Tot_Drug_Cst)2024 Drug cost: $2,600,930 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015130891$1,411,339
2016120706$947,728
2017135853$1,455,239
2018133966$2,053,950
2019155982$2,140,815
20201521,056$1,908,264
20211621,076$1,522,759
20221791,090$1,704,819
20231811,116$1,809,225
20242341,300$2,600,930

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$3.3K$6.6K2015 Medicare payment: $6,641 (USD; DME_Suplr_Mdcr_Pymt_Amt)2019 Medicare payment: $6,332 (USD; DME_Suplr_Mdcr_Pymt_Amt)2020 Medicare payment: $4,116 (USD; DME_Suplr_Mdcr_Pymt_Amt)2021 Medicare payment: $3,792 (USD; DME_Suplr_Mdcr_Pymt_Amt)2022 Medicare payment: $40 (USD; DME_Suplr_Mdcr_Pymt_Amt)2023 Medicare payment: $2,185 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
2015N/R91$6,641
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/R45$6,332
2020N/R39$4,116
2021N/R37$3,792
2022N/R11$40
2023N/R11$2,185
2024N/RN/RN/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
96413Administration of chemotherapy into vein, 1 hour or less75234$95
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more214595$93
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more231381$60
G2211Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's153211$12
96372Injection of drug or substance under skin or into muscle93301$11

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
RevlimidLenalidomide902,445$1,633,601
LenalidomideLenalidomide16448$266,940
InqoviDecitabine/Cedazuridine13364$106,493
EliquisApixaban1335,370$99,939
XareltoRivaroxaban613,030$56,119

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.89$1,997AstraZeneca Pharmaceuticals LP
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Nishanth Sukumaran, MD?

Tedicare shows public-source Medicare data for Nishanth Sukumaran, MD (NPI 1538328844), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nishanth Sukumaran, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Nishanth Sukumaran, MD?

Nishanth Sukumaran, MD is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Nishanth Sukumaran, MD have Open Payments data?

Nishanth Sukumaran, MD has 89 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.